Fennec Pharmaceuticals Inc.
TSX:FRX.TOBiotechnology
-$0.22 today
- Market cap
- $676.80M
- Beta
- 1.08
- P/E (TTM)
- -36.5
- EPS (TTM)
- -$0.24
Volume 0.00M
Average 0.00M
FRX.TO Total Current Liabilities
All obligations due within one year.
Fennec Pharmaceuticals Inc.TSX: FRX.TO
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 14.2% from a year ago
Total current liabilities stood at $9.56M at the end of Q1 FY2026, up 14.2% from a year earlier and down 8.9% from the prior quarter. Over 3 fiscal years it compounded at +31.6% a year.
Context
- Total current liabilities amounted to 13.3% of total assets at the end of Q1 FY2026, down 4.7 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +14.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 10.5M USD
- Year-over-year change
- +51.7%
- 4-year CAGR
- +58.7%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.5M | +51.7% |
| FY2024 | 2024-12-31 | 6.92M | -8.4% |
| FY2023 | 2023-12-31 | 7.55M | +63.9% |
| FY2022 | 2022-12-31 | 4.61M | +178.7% |
| FY2021 | 2021-12-31 | 1.65M | — |
Total Current Liabilities vs competitors
How FRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +14.2% is the 6th highest of 8, against a peer median of +67.8%.
- Total current liabilities amounts to 13.3% of total assets for FRX.TO, versus a peer median of 14.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$158.44M CAD | +67.8% | -41.8% | 14.2% | |
| Mar 2026 | CA$88.75M CAD | +17.4% | — | 17.0% | |
| Mar 2026 | $67.73M USD | -12.4% | -16.9% | 12.3% | |
| Mar 2026 | $61.96M USD | -22.6% | -7.6% | 22.3% | |
PRN.TOProfound Medical Corp. | Mar 2026 | $10.61M USD | +100.5% | +13.2% | 14.4% |
| Mar 2026 | $9.56M USD | +14.2% | +31.6% | 13.3% | |
| Mar 2026 | $7.37M USD | +234.9% | +10.7% | 5.1% | |
| Apr 2026 | CA$6.69M CAD | +179.0% | -1.9% | 31.3% | |
| Peer median (excluding FRX.TO) | — | +67.8% | -4.8% | 14.4% | |
Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21.1M | 23.77M | 13.27M | 26.63M | 36.72M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 1.55M | 8.81M | 12.88M | 23.18M |
| Inventory | 0 | 576K | 2.16M | 1.06M | 1.56M |
| Other Current Assets | 253K | 63K | 44K | 466K | 1.37M |
| Total Current Assets | 22.39M | 26.73M | 26.86M | 44.12M | 66.56M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 2.79M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 27K | 211K | 6K | 822K | 710.62K |
| Total Non-current Assets | 27K | 211K | 6K | 822K | 3.5M |
| Total Assets | 22.41M | 26.94M | 26.86M | 44.95M | 70.07M |
| Account Payables | 777K | 2.39M | 3.78M | 3.24M | 4.63M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 248K | 247.55K |
| Other Current Liabilities | 0 | 0 | 0 | 0 | (10.25K) |
| Total Current Liabilities | 1.65M | 4.61M | 7.55M | 6.92M | 10.5M |
| Long-term Debt | 4.99M | 24.9M | 30.93M | 19.34M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 24.56M |
| Other Non-current Liabilities | 0 | 0 | 0 | 24.56M | 0 |
| Total Non-current Liabilities | 4.99M | 24.9M | 30.93M | 43.9M | 24.52M |
| Total Liabilities | 6.64M | 29.51M | 38.49M | 50.82M | 35.02M |
| Common Stock | 140.8M | 142.59M | 144.31M | 145.61M | 189.56M |
| Retained Earnings | (179.49M) | (203.2M) | (219.25M) | (219.68M) | (229.36M) |
| Accumulated OCI | 1.24M | 1.24M | 1.24M | 1.24M | 1.24M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 15.77M | (2.57M) | (11.62M) | (5.87M) | 35.05M |
| Total Debt | 4.99M | 24.9M | 30.95M | 19.34M | 0 |
| Net Debt | (16.11M) | 1.13M | 17.69M | (7.29M) | (36.72M) |
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$19.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.